1 / 72

SYNCOPE Nora Goldschlager, M.D.

SYNCOPE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology – San Francisco General Hospital UCSF Disclosures: None. SCOPE OF THE PROBLEM. Cumulative lifetime incidence in general population up to 35% 1% of all hospital admissions 3% of all ER visits; up to 65% are vasovagal

fausta
Télécharger la présentation

SYNCOPE Nora Goldschlager, M.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SYNCOPE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRSCardiology – San Francisco General HospitalUCSF Disclosures: None

  2. SCOPE OF THE PROBLEM • Cumulative lifetime incidence in general population up to 35% • 1% of all hospital admissions • 3% of all ER visits; up to 65% are vasovagal • 6% incidence in institutionalized elderly • Prevalence: 7 - 47% in young, healthy subjects; unknown in elderly • Up to 30% of patients may have no diagnosis established at hospital discharge • 6% annual mortality if no cause established • 12 - 25% recurrence

  3. 50 40 30 20 10 0 Cardiac Mortality % Noncardiac Unknown Yr. of FU: 0 1 2 3 4 5 No. at risk: 433 380 349 295 179 44 Kapoor Medicine 69:1990 N = 433 Sudden death: 37%

  4. SURVIVAL IN SYNCOPAL PATIENTS No syncope Vasovagal & other causes (OH, med Rx) Unknown cause Neurologic cause Cardiac cause 1.0 .8 .6 .4 .2 0 Probability of survival 0 5 10 15 20 25 Follow-up (yr) Soteriades et al NEJM 2002;347:878 (Framingham) N = 822/7814

  5. Males Females Prevalence (%) 0 7 14 21 Age (yrs) PREVALENCE OF SYNCOPE BY AGE 50 40 30 20 10 0 Ganzeboom et al AJC 4.15.03

  6. 15% 15% 25% 30% 30% 15% 40% 30% YOUNGER ADULTS ELDERLY OH, CSS, situational, seizures, drugs 1° arrhythmia, LV obstruction OH, situational,seizures, drugs 1° arrhythmia Vasovagal Undetermined Cardiogenic Other causes

  7. ETIOLOGY OF FIRST SYNCOPE IN PATIENTS > 65 YEARS % • Reflex-mediated (VVS, CSS, situational) 13-30% • Orthostatic 12 • Cardiac Arrhythmic 8 Nonarrhythmic 3 • Drug-induced 8 • CNS 6 • Unexplained 49 Roussanov et al, Am J Geriatric Cardiol 2007;16:249 N=304 (VA patients)

  8. FEATURES OF UNEXPLAINED SYNCOPE IN OLDER PATIENTS • High incidence of comorbid conditions • 24% recurrence rate •Concurrent BP and HF Rx increases susceptibility to + HUT • Only 9% had an etiology established during follow-up • Lower diagnostic yield of history and tests compared in younger patients Roussanov et al, Am J Geriatric Cardiol 2007;16:249 N=304 (VA patients)

  9. PROGNOSIS IN UNEXPLAINED SYNCOPE IN PATIENTS > 65 1.0 .75 .50 .25 0 Control Syncope Proportion of pts alive 0 1 2 3 Yrs FU Roussanov et al Am J Geriatric Cardiol 2007; 16:249 N = 304 VA pts

  10. EVALUATION OF SYNCOPE: PERTINENT HISTORY • • Precipitating factors • - Posture changes (orthostatic hypotension) • - Cough, swallowing, micturition, defecation (“situational” syncope) • - Exercise (consider aortic stenosis, HOCM, VT) • - Head turning, Valsalva (suggests carotid sinus syndrome) • • Prodromal symptoms • • Speed of onset and recovery (prolonged recovery suggests vasovagal syncope) • • Aura (suggests seizure) • Hx heart disease (predicts cardiac syncope: 95% specificity <50%>)

  11. NATURAL HISTORY OF AORTIC STENOSIS Onset of Sx With AVR 100 75 50 25 0 Asx stage Without AVR % Survival CHF Angina Syncope 10 20 30 Years

  12. • Drugs - Diuretics ( hypokalemia, hypomagnesemia) - Digitalis (AVB, VT-classically bidirectional) - Antihypertensives - Antiarrhythmic agents (proarrhythmia) - Ophthalmic -blockers - Antianginal medications (preload and afterload reduction) - QT prolonging drugs (www.torsades.org) - OTC drugs - Herbs - Illicit drugs, alcohol - β-blockers • Family historyof sudden death (congenital long QT syndrome, hypertrophic obstructive cardiomyopathy) • Known rhythm abnormality (e.g., WPW) EVALUATION OF SYNCOPE: PERTINENT HISTORY

  13. Exercise-induced RVOT VT

  14. Tussive bradycardia

  15. Deglutition bradycardia Continuous strips

  16. CONGENITAL LQTS • 1:10,000 is a gene carrier • 3-4,000 sudden deaths/yr, mostly young patients • 10% sudden deaths in untreated patients • 30% of sudden or aborted sudden deaths occur as 1st event • Female gender • About 10% have normal QTC; about 30% have borderline QTC

  17. CLUES TO ETIOLOGY OF SYNCOPE FROM PHYSICAL EXAMINATION • Left ventricular impulse abnormalities suggesting past myocardial infarction • Ventricular hypertrophy (need for AV synchrony) • Ventricular gallops • Murmurs (aortic stenosis, hypertrophic obstructive cardiomyopathy) • Pulmonary hypertension • Mitral valve prolapse (PSVT, VT, autonomic dysfunction) • Carotid sinus massage indicating CSH

  18. CAROTID SINUS MASSAGE • Generally accepted contraindications - Carotid bruits - Prior endarterectomy - Prior TIA or CVA - Known cerebrovascular disease • Responses to CSM - Bradycardia / asystole usually abrupt - Hypotension often not abrupt, and outlasts the CSM - Complications (< 1%): TIA, transient paresis, visual disturbances

  19. CLUES TO ETIOLOGY OF SYNCOPE FROM 12-LEAD ECG • Long QT interval • Prior MI (substrate for VT) • Epsilon wave, anterior (V1-3) T inversion, QRS duration V1-3 / V4-6 > 1.2, suggesting RV dysplasia • Brugada pattern • Short QT interval (with tall symmetric T waves) • Ectopy • Bradycardia • AV conduction delay / block • Bifascicular block • Ventricular hypertrophy (need for AV synchrony)

  20. Epsilon wave of RV dysplasia V1 V2 V3 Marcus, Fontaine PACE 6.95

  21. RV DYSPLASIA • Young pt • Can present as syncope or aborted sudden death • ECG: - Anterior T inversion V1-3 - Prominent anterior forces - RIVCD - Delayed S wave V1-2 • MRI is usually (but not always) diagnostic (fat replacement)

  22. RV dysplasia

  23. BRUGADA SYNDROME

  24. BRUGADA SYNDROME

  25. OUTCOME IN PTS WITH BRUGADA ECG 1.0 .8 .6 .4 .2 0 Asymptomatic (57%) Free of events (SD, VF) Syncope (22%) Sudden death (21%) p = 0.00001 0 100 200 300 Mos Brugada et al Circulation 2002; 105:73 N = 334, all EPS 63% of syncopal pts had VT induced

  26. PROGNOSIS OF SYNCOPE IN BRUGADA SYNDROME 1.0 .8 .6 .4 .2 0 Asymptomatic Syncope Free of Appropriate ICD Rx Sudden death 0 12 24 36 48 60 Follow-up (mos) Antzelevitch et al Circulation 2005; 111:659 N=258 (Registry)

  27. • Aortic stenosis • Hypertrophic cardiomyopathy (especially obstructive) • Regional wall-motion disorders (substrate for VT) • Right ventricular dysplasia • Calcified mitral / aortic annulus ( AV block incidence) • Intracardiac tumor • Mitral valve prolapse • Repaired congenital heart disease • Normal echo ROLE OF ECHOCARDIOGRAPHY IN SYNCOPE

  28. NONARRHYTHMIC CARDIAC SYNCOPE: OBSTRUCTION TO FLOW • Aortic stenosis - LV baroceptor stimulation with reflex peripheral vasodilation - Ventricular arrhythmias - Transmural ischemic injury with LV dysfunction • Hypertrophic obstructive cardiomyopathy • Tumor • Primary pulmonary hypertension, pulmonic stenosis • Pulmonary embolism

  29. Syncope in aortic stenosis Recorded during syncopal spell. BP unobtainable.

  30. Syncope in aortic stenosis Lead III: During syncopal spell

  31. SYNCOPE IN HYPERTROPHIC CARDIOMYOPATHY - 1 • Causes - SVT (especially AF) - VT - LV outflow tract gradient - Abnormal baroreceptor reflexes - Ischemia • EP studies unreliable • -blockers, disopyramide and Ca++ channel blockers do not reduce incidence of SD

  32. SYNCOPE IN HYPERTROPHIC CARDIOMYOPATHY - 2 • ICD indicated for high risk patients - Family hx syncope/sudden death - LVH > 3 cm - Aborted sudden death - Nonsustained VT on Holter

  33. SYNCOPE IN PULMONARY HYPERTENSION • Usually exertional or immediately post-exercise • “Fixed” right sided obstruction due to high pulmonary vascular resistance • Inability to increase CO in response to SVR • Decreased cerebral perfusion

  34. SYNCOPE IN SYSTOLIC HEART FAILURE • In patients with syncope, heart failure is an independent predictor of mortality • Syncopal patients with ICDs have appropriate therapies delivered • SCD-HeFT: - Predictors of syncope: QRSd > 120 ms, NYHA III, no beta blocker - Not predictors: EF, NSVT, AF, other HF Rx - 16% with ICD had syncope; 41% had appropriate shock (vs 12% with no syncope) - Syncope was predictor of total and CV mortality, but not sudden death and did not differ among ICD, amio, or placebo pts - ICDs did not reduce mortality in syncope patients

  35. NEUROCARDIOGENIC (VASOVAGAL) SYNCOPE • Occurs at all ages • 17 - 35% suffer significant injury • 5 - 7% have fractures •Up to 4% of pts diagnosed with VVS may have cardiac syncope

  36. FEATURES OF HISTORY IN VVS • Usually occurs in upright position • Rare during exercise • 3 phases: prodrome, loss of consciousness, postsyncopal period • May have specific triggers: pain, trauma, stress, “situational” (swallow, micturition, defecation) • Peri-event amnesia common • Association with chronic fatigue syndrome, depression, somatic disorders • May run in families •  frequency around menses

  37. VV (%) Arrhythmic (%) VASOVAGAL vs ARRHYTHMIC* SYNCOPE P Male < .001 Age > 54 < .001 Supine NS Upright NS Precipitant < .001 No presyncope NS Warning NS Diaphoresis < .001 0 20 40 60 80 100 *VT + AVB Calkins et alAJM 98:1995

  38. VV (%) Arrhythmic (%) VASOVAGAL vs ARRHYTHMIC* SYNCOPE P Fatigue Post < .001 Confusion NS Palpitations NS Incontinence .02 Injury NS Major Injury NS Recovery > 0” < .001 0 20 40 60 80 100 *VT + AVB Calkins et alAJM 98:1995

  39. HEAD UP TILT NEUROCARDIOGENIC SYNCOPE  LV volume  Venous return  LV contractility Peripheral venous pooling Mechanoreceptor stimulation (myocardial C fibers)  Vagal tone Peripheral vasodilation Vasomotor center  adrenergic tone Hypotension Bradycardia or asytole

  40. VVS: PHARMACOLOGIC THERAPY • Anticholinergic agents - Disopyramide* (effect vs placebo is controversial) - Scopolamine • Negative inotropic agents - Disopyramide* • Fludrocortisone • Vasopressin • Alpha-adrenergic agonists - Ephedrine - Etilephrine - Theophylline - Dexedrine - Midodrine • Serotonin reuptake inhibitors * Watch for urinary retention, torsades de pointes VT

  41. Effect vs placebo is controversial and not supported in RCTs - Dual chamber - Rate-drop response or other algorithm which detects heart rate, then tachypaces while periodically searching for spontaneous rhythm VVS: PACEMAKER THERAPY

  42. VVS: PACING vs -BLOCKADE (SYDIT) 1.0 0.9 0.8 0.7 0.6 Pacemaker % syncope free pts P = 0.0031 Atenolol 0 200 400 600 800 1000 Days Ammirati et al Circulation 2001; 104:52 N = 93

  43. “ORTHOSTATIC TRAINING” FOR REFRACTORY NEUROCARDIOGENIC SYNCOPE N = 47, mean age 16 5 in hospital training sessions 40 min BID standing against wall at home Results: (FU 18 ± 5 mos) 96% had – HUT (Control 26%) 0% had syncope (Control 57%) Girolamo et al Circulation 1999;100:1798

  44. LEG CROSSING AND MUSCLE TENSING TO ABORT / MITIGATE VASOVAGAL SYNCOPE • N = 21 • At onset of sx, leg crossing with tensing of abdominal, leg and buttock muscles • BP and HR stabilized in all pts in 3 - 6" • 5 / 20 aborted syncope • 15 / 20 had delayed onset of syncope by 0.5 - 11' • At 10 mo FU, 16 / 19 benefited from maneuver • Similar benefit for cardiac pacing Krediet at al, Circulation 2002;106:1684

  45. ISOMETRIC ARM EXERCISE TO ABORT VASOVAGAL SYNCOPE Control 2 min handgrip HR 112 90 68 45 BP 178 156 133 111 89 67 44 Asx 11% Syncope 47% Asx 63% Syncope 5% Brignole et al JACC 2002;40:2053 N = 19

  46. FALLS: SCOPE OF THE PROBLEM • 30% of pts > 65 fall / yr • 60% of pts in long-term care facilities fall / yr • 10 - 20% result in injury • 2 - 6% result in fractures • Usually unwitnessed • 30% have LOC with CSM; 80% had amnesia Kenny et al SAFEPACE JACC 2001;38 N = 175

More Related